Is lipoxins A4 a better alternative to anti-TNF-alpha antibody to prevent and treat diabetic macular edema and retinopathy?
Das
Undurti N
UN
D000906:Antibodies / Q000008:administration & dosage / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000517:prevention & control*; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D006801:Humans; D044045:Lipoxins / Q000627:therapeutic use*; D008269:Macular Edema / Q000188:drug therapy* / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000906:Antibodies; D005231:Fatty Acids, Unsaturated; D044045:Lipoxins; D014409:Tumor Necrosis Factor-alpha; C040527:lipoxin A4